CytomX Therapeutics (CTMX) Income towards Parent Company (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Income towards Parent Company data on file, last reported at -$18.2 million in Q1 2026.

• Quarterly Income towards Parent Company fell 177.57% year-over-year to -$18.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$55.3 million (down 232.94% YoY) and the FY2025 annual result came in at -$13.5 million, down 142.46% from the prior year.
• Income towards Parent Company improved to -$18.2 million in Q1 2026, from -$22.7 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $23.5 million in Q1 2025 to a low of -$32.0 million in Q1 2022.
• A 5-year average of -$5.9 million and a median of -$3.3 million in 2023 frame the typical range for Income towards Parent Company.
• The widest YoY moves for Income towards Parent Company: up 2155.2% in 2024, down 501.1% in 2024.
• Tracing CTMX's Income towards Parent Company over 5 years: stood at -$8.8 million in 2022, then soared by 109.54% to $837000.0 in 2023, then jumped by 2155.2% to $18.9 million in 2024, then tumbled by 220.12% to -$22.7 million in 2025, then increased by 19.52% to -$18.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$18.2 million (Q1 2026), -$22.7 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.